ICAM-1 as a Potential Target for Treatments Blocking the Host Response in Stroke

この論文にアクセスする

この論文をさがす

著者

抄録

Leukocytes and their actions have been implicated in the pathogenesis of microcirculatory and cytotoxic perturbations in experimental stroke models. Experiments in several models of stroke patho-physiology have demonstrated the important role of endothelial intercellular adhesion molecule (ICAM-1) in targeting the leukocyte response to the ischemic brain region and transmigration of polymorphonuclears into the parenchyma. In this article, investigations suggesting beneficial effects of anti-adhesion therapies blocking the endothelial ICAM-1 or its counter-receptor CD11/CD18 on leukocytes are reviewed. This evidence should be viewed also in the context of human stroke, which has also recently been shown to overexpress ICAM-1 molecules on the infarcted endothelium. Well-tolerated monoclonal antibodies (mAb) blocking ICAM-1 might eventually be shown to possess therapeutic value acutely in clinical stroke victims, perhaps in combination with thrombolytic therapy.

収録刊行物

  • Keio journal of medicine  

    Keio journal of medicine 45(3), 254-262, 1996-09-01 

    The Keio Journal of Medicine

参考文献:  39件

参考文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

各種コード

  • NII論文ID(NAID)
    10021986902
  • NII書誌ID(NCID)
    AA00710216
  • 本文言語コード
    ENG
  • 資料種別
    REV
  • ISSN
    00229717
  • データ提供元
    CJP書誌  J-STAGE 
ページトップへ